AI Article Synopsis
- A study in the Netherlands focused on advanced-stage ovarian cancer revealed that 14% of women diagnosed between 2008 and 2016 received no cancer-directed treatment.
- Factors such as age, higher FIGO stage, lower socioeconomic status, and co-morbidities were linked to a lack of treatment, with the trend increasing from 11% to 16% over the years.
- The primary reasons for not pursuing treatment were the patient's personal choice (40%) and their poor health condition (29%).
Article Abstract
Objectives: A significant proportion of women with advanced-stage ovarian cancer receive no cancer-directed treatment and limited research has been devoted to this group. This population-based study aimed to gain insight into treatment patterns and trends in patients with advanced epithelial ovarian cancer in the Netherlands and the main reasons for deciding for no cancer-directed treatment.
Methods: All patients diagnosed with advanced epithelial ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) classification IIB-IV, between 2008 and 2016 were identified from the Netherlands Cancer Registry. Trends in the number of patients receiving cancer-directed treatment were analyzed. Multivariable logistic regression analysis was used to identify factors associated with no cancer-directed treatment. The main reasons for no cancer-directed treatment were analyzed.
Results: A total of 9303 patients were included, of whom 14% (n=1270) received no cancer-directed treatment while 67% (n=6218) received a combination of cytoreductive surgery and chemotherapy. Some 15% (n=1399) received chemotherapy only, and 4.5% (n=416) surgical resection or hormonal therapy only. The proportion of patients receiving no cancer-directed treatment was higher in 2014-2016 (16%, n=496/3175) compared with 2008-2010 (11%, n=349/3057, p<0.001). Associated factors with no cancer-directed treatment were higher age, FIGO stage IV, lower socioeconomic status, co-morbidity, and more recent years of diagnosis (p<0.001). Main reasons for no cancer-directed treatment were patient's choice (40%) and poor condition of the patient (29%).
Conclusions: The proportion of patients with advanced epithelial ovarian cancer not receiving cancer-directed treatment has increased in the last decade in the Netherlands. Patient's choice was the main reason for the decision to undergo no cancer-directed treatment, which indicates patient involvement in the decision-making process. The second most common reason for no cancer-directed treatment was poor condition of the patient, which might indicate careful selection of patients for treatment. Decision-making regarding treatment is well-considered, but more insight is needed, especially from the patient's perspective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ijgc-2019-000489 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) for the treatment of patients with malignant pleural effusion: study protocol for the Danish phase-I PITAC-OPC5 study.
Pleura Peritoneum
December 2024
Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Odense University Hospital, Odense, Denmark.
Objectives: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) is a minimally invasive cancer-directed therapy for patients with malignant pleural effusion (MPE) and/or pleural metastasis (PLM). PITAC is based on Pressurized IntraPeritoneal Aerosol Chemotherapy, which has proven to be safe and feasible. Since 2012, 47 PITACs have been published, and prospective data on feasibility, safety and potential local response are lacking.
View Article and Find Full Text PDFA phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol.
BMC Cancer
December 2024
Department of Radiation Oncology, University of California, 200 Medical Plaza Driveway, Suite #B265, Los Angeles, CA, 90025, USA.
Background: Many patients with head and neck cancer are not candidates for standard of care definitive treatments though often require palliative treatments given the frequent symptoms associated with head and neck cancer. While existing palliative radiotherapy regimens can provide adequate symptom control, they have limitations particularly with respect to local control which is becoming more important as advances in systemic therapy are improving survival. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) is a novel radiotherapy regimen which leverages advances in radiotherapy treatment technology and extended interfraction intervals to enable adaptive radiotherapy and possible synergy with the immune system.
View Article and Find Full Text PDFThe pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders.
J Geriatr Oncol
December 2024
Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Introduction: We performed a qualitative study to explore key stakeholders' perspectives about the impact of frailty on ovarian cancer care and evaluate a candidate prehabilitation intervention.
Materials And Methods: We conducted semi-structured interviews with patient-caregiver dyads and multi-disciplinary clinicians. Patients were ≥ 50 years of age with a new diagnosis of advanced stage (III/IV) ovarian cancer who received cancer-directed treatment (chemotherapy and/or surgery) during the past year and met criteria as pre-frail or frail using the FRAIL scale.
Development and Validation of a Survival Prediction Model for Patients With Pancreatic Cancer.
Clin Transl Gastroenterol
December 2024
Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
Article Synopsis
- A survival prognostication model was developed for pancreatic ductal adenocarcinoma (PDAC) patients using clinical data, patient-reported symptoms, and treatment specifics to aid in their treatment decisions.
- The study analyzed data from 17,450 PDAC patients in Ontario over a 13-year period, finding significant predictors of survival, including tumor location, disease stage, hospitalizations, heart failure, and various pain and performance scores.
- The model demonstrated good predictive accuracy with a C index of 0.76, suggesting it could enhance shared decision-making between patients and healthcare providers regarding treatment options.
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?
Cancer Res Treat
November 2024
Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
Antibody Drug Conjugates (ADCs) are a novel class of therapeutics that structurally are composed by an antibody directed to a tumour epitope connected via a linker to a cytotoxic payload, and that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology and design of ADCs, as well as we describe the results of different studies evaluating ADCs in lung cancer directed to several targets including HER2, HER3, TROP2, MET, CEACAM5 and DLL3, among others.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!